US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline
Executive Summary
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
You may also be interested in...
Initial List Of US Essential Medicines Focuses On Acute Care
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.
Reorganization Of US FDA’s Office Of Regulatory Affairs Will Deliver More Preemptive Inspectorate
Top officials plan to coordinate field operations better by creating agencywide IT systems that could prevent quality failures in programs including drugs, not just respond to them. Siloed systems were blamed for missed opportunity to stem infant formula contamination and prevent subsequent shortages.